AstraZeneca announces that results from a Phase III pre-exposure prophylaxis (prevention) trial against COVID-19 showed that AstraZeneca's sipavibart (formerly AZD3152), an investigational long-acting antibody (LAAB), demonstrated a 'statistically significant' reduction in the incidence of Covid compared to control (tixagevimab/cilgavimab or placebo) in an immunocompromised patient population.

The trial met both primary endpoints; the first being the relative risk reduction of symptomatic COVID-19 caused by any SARS-CoV-2 variant, and the second being the relative risk reduction of infections caused by SARS-CoV-2 variants not containing the F456L mutation.

Sipavibart has the potential to prevent COVID-19 in immunocompromised individuals, and we will now work with regulatory authorities around the world to bring Sipavibart to these vulnerable patients', commented Iskra Reic, Executive Vice President of Vaccines and Immune Therapies at AstraZeneca.

Copyright (c) 2024 All rights reserved.